Recognizing but not harming. Borderline B‐cell lymphoid proliferations

In the last years several borderline B-cell lymphoid proliferations have been recognized that lie at interface between benign and malignant. These lesions can be divided in two groups; those considered precursor of well malignancies group indolent lymphomas with limited potential for progression. Precursor are monoclonal share many genetic features their malignant counterpart. The first lesion was gammopathy undetermined significance. Thereafter, widespread use immunohistochemistry, fluorescence-activated cell sorting analysis molecular techniques samples led to recognition other such as lymphocytosis, situ follicular neoplasia mantle neoplasia. second disorders comprises without a counterpart among currently lymphoma entities; these include pediatric-type lymphoma, pediatric nodal marginal zone duodenal-type lymphoma. Despite clonal nature, conservative treatment has shown sufficient most cases. diagnostic criteria precursor/indolent proliferations, recent advances understanding progression lymphomagenesis current recommendations will discussed. order avoid unnecessary potentially harmful therapy, need diagnosed correctly.